Ingemar Lagerlöf

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients

Lasse Hjort Jakobsen, Fredrik Ellin, Knut B. Smeland et al. · British Journal of Haematology · 2020 · 23 citations · Full text

Medicine, Oncology, Immunotherapy +11

No excess long‐term mortality in stage I‐IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

Ingemar Lagerlöf, Harald Holte, Ingrid Glimelius et al. · British Journal of Haematology · 2019 · 22 citations

Medicine, Oncology, Radiation Oncology +11

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

David Lewis, Mats Jerkeman, Lexy Sorrell et al. · Blood · 2024 · 21 citations

Medicine, Immunology, Oncology +7

Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma

Anne Andersson, Gunilla Enblad, Björn Tavelin et al. · British Journal of Cancer · 2008 · 19 citations · Full text

Medicine, Oncology, Cancer Epidemiology +15

Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

Ingemar Lagerlöf, Helena Fohlin, Gunilla Enblad et al. · Journal of Clinical Oncology · 2022 · 16 citations · Full text

Medicine, Oncology, Radiation Oncology +15